Menu Search
Equities

NRX Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
B1Q:FRA

NRX Pharmaceuticals Inc

Actions
  • Price (EUR)1.40
  • Today's Change-0.11 / -7.28%
  • Shares traded1.13k
  • 1 Year change-54.55%
  • Beta1.9615
Data delayed at least 15 minutes, as of Feb 06 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

  • Revenue in USD (TTM)242.00k
  • Net income in USD-38.06m
  • Incorporated2017
  • Employees2.00
  • Location
    NRX Pharmaceuticals Inc1201 ORANGE STREET, SUITE 600WILMINGTON 19801United StatesUSA
  • Phone+1 (484) 254-6134
  • Fax+1 (302) 575-1642
  • Websitehttps://www.nrxpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.